Ductal Carcinoma in Situ Has Comparable Prognosis but Different Risk Factors with Ductal Carcinoma in Situ with Micro Invasion

W. Liu,S. Wang,Y. Tang,J. Jin,Y. W. Song,W. Wang,Y. Liu,H. Fang,H. Ren,X. Liu,Z. Yu,Y. X. Li

DOI: https://doi.org/10.1016/j.ijrobp.2017.06.669

2017-01-01

Abstract:To evaluate the treatment outcome and risk factors of breast cancer patients with ductal carcinoma in situ (DCIS) and ductal carcinoma in situ with micro invasion (DCIS-MI). 994 women treated from 1998 to 2011, including 622 DCIS and 372 DCIS-MI were retrospectively analyzed. Overall survival (OS), disease-free survival (DFS) and local recurrence (LR) were calculated by the Kaplan-Meier method and compared by log-rank test. Competing risk was used to evaluate the efficacy of different treatments on local control. The clinical and treatment characteristics of the 2 groups were shown in table. With a median follow up time of 49 months (IQR 30 - 79 months), there were no significant differences in 5-year OS (99.1% vs. 98.9%, p = 0.451), DFS (96.3% vs. 96.4%, p = 0.570), and LR (2.1% vs. 2.5%, p = 0.940) between DCIS-MI and DCIS group. The following variables were included in univariate analyses to identify risk factors: age, tumor size, number of tumor foci, tumor grade, ER/PR status, Her2 status, surgery type, radiotherapy, hormone therapy, chemotherapy. For DCIS group, patients with Her2 positive disease had worse 5y OS compared with Her2 negative (97.1% vs. 99.5%, p = 0.021). Compared with BCS, TM achieved better 5y DFS (99.1% vs. 92.6%, P= 0.008), and significantly reduced 5y cumulative LR (0.5% vs. 5.0%, p<0.001). For DCIS-MI group, the number of tumor foci ≥2 was an adverse factor for OS and DFS as compared with single tumor (5y OS: 90.2% vs. 100%, p = 0.001; 5y DFS: 84.6% vs. 98.7%, p = 0.009). The difference in 5y cumulative LR was not significant between TM and BCS (0.45% vs. 3.96%, p=0.181). For patients treated with BCS, there were no significant differences in 5y LR between those with and without postoperative RT (DCIS group: 4.8% vs. 4.5%, p=0.175; DCIS-MI group: 3.4% vs. 5.5%, p=0.747). Breast DCIS and DCIS-MI both have very favorable outcomes. DCIS patients with Her2 positive disease and DCIS-MI patients with multifoci tumors have unfavorable survival and might need more aggressive treatment.Tabled 1Abstract 2077; Table General characteristics of the patientsVariablesDCIS N(%)DCIS-IM N(%)pvariablesDCIS N(%)DCIS-IM N(%)pAge ≥45396(63.7)242(65.1)0.659Her2+135(21.7)109(29.3)<0.001Tumor foci≥238(6.1)25(6.7)0.927Surgery<0.001Tumor≥2cm304(48.9)127(34.1)<0.001TM381(61.3)270(72.6)Tumor grade<0.001BCS241(38.7)102(27.4) G1115(18.5)27(7.3)RT after BCS155(69.2)77(82.8)0.013 G254(8.7)23(6.2)No RT after BCS69(30.8)16(17.2) G3163(26.2)89(23.9)Hormone therapy368(59.2)204(54.8)0.019 Unknown290(46.6)233(62.6)Target therapy2(0.3)4(1.1)0.304ER and/or PR+442(71.1)238(64.0)<0.001Chemotherapy47(7.6)121(32.5)<0.001 Open table in a new tab